According to Junyao Health's announcement, the company plans to increase the capital of the holding subsidiary Junyao Runying Biotechnology Co., Ltd. by 220 million yuan by transferring debt to capital reserves. All rights corresponding to this portion of the capital reserve will be exclusively enjoyed by the company. After the capital increase was completed, Junyao Runying's registered capital and current shareholding structure remained unchanged. It is still a holding subsidiary of the company, and the scope of the consolidated statement remains unchanged. This capital increase does not constitute a related transaction or major asset restructuring. It has been reviewed and approved by the 3rd meeting of the 6th board of directors of the company, and there is no need to submit it to the shareholders' meeting for review.

According to Junyao Health's announcement, the company plans to increase the capital of the holding subsidiary Junyao Runying Biotechnology Co., Ltd. by 220 million yuan by transferring debt to capital reserves. All rights corresponding to this portion of the capital reserve will be exclusively enjoyed by the company. After the capital increase was completed, Junyao Runying's registered capital and current shareholding structure remained unchanged. It is still a holding subsidiary of the company, and the scope of the consolidated statement remains unchanged. This capital increase does not constitute a related transaction or major asset restructuring. It has been reviewed and approved by the 3rd meeting of the 6th board of directors of the company, and there is no need to submit it to the shareholders' meeting for review.